A Trial on the Remission Rates of Type I Autoimmune Pancreatits With High-risk of Recurrence (AIP;MMF)
A Multicenter, Prospective, Randomized Controlled Trial on the Remission Rate of Type I AIP With High-risk of Recurrence Patients Receiving Glucocorticoid Maintenance Therapy/Glucocorticoid Combined With Mycophenolate Mofetil Maintenance Therapy
Autoimmune pancreatitis (AIP) is an autoimmune disease with low incidence rate and involving the pancreas. In China, type I AIP is predominant. Glucocorticoids (GC) have a significant therapeutic effect. Even though a consensus has been reached on the effective initial GC treatment dose, type I AIP is prone to recurrence after GC induction and maintenance therapy. Currently, there is no consensus on how to reduce the disease recurrence rate in high-risk type I AIP patients. Multiple studies have shown that immunosuppressants (IM) combined with GC can effectively reduce the disease recurrence rate in IgG4 RD patients, including azathioprine, mycophenolate mofetil (MMF), etc. Among them, the incidence of adverse reactions in MMF is relatively low. As a special type of IgG4-RD, there is currently no prospective study evaluating the efficacy and safety of GC combined with MMF treatment in high-risk recurrent type I AIP patients. The smooth implementation of this project can provide new treatment ideas and evidence-based medicine for reducing the recurrence rate of high-risk type I AIP.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Autoimmune pancreatitis (AIP) is an autoimmune disease with low incidence rate and involving the pancreas. It can be divided into type I AIP and type II AIP. In China, type I AIP is predominant, accompanied by elevated IgG4 levels, diffuse or segmental pancreatic enlargement, and irregular narrowing of the pancreatic duct. Glucocorticoids (GC) have a significant therapeutic effect. Even though a consensus has been reached on the effective initial GC treatment dose, type I AIP is prone to recurrence after GC induction and maintenance therapy. Currently, there is no consensus on how to reduce the disease recurrence rate in high-risk type I AIP patients. The International Pancreatic Society has released an international consensus on AIP, indicating that the risk factors for AIP recurrence are still unclear. The following are possible signs of recurrence: IgG4>4 times the upper limit of normal value before treatment; The serum IgG4 level remained high after GC treatment; Pancreatic diffuse enlargement; IgG4-SC with proximal bile duct involvement; Involvement of extrapancreatic organs.Multiple studies have shown that immunosuppressants (IM) combined with GC can effectively reduce the disease recurrence rate in IgG4 RD patients, including azathioprine, mycophenolate mofetil (MMF), etc. Among them, the incidence of adverse reactions in MMF is relatively low. As a special type of IgG4-RD, there is currently no prospective study evaluating the efficacy and safety of GC combined with MMF treatment in high-risk recurrent type I AIP patients. The smooth implementation of this project can provide new treatment ideas and evidence-based medicine for reducing the recurrence rate of high-risk type I AIP.Main research objective: To evaluate the impact of corticosteroid monotherapy and corticosteroid combined with MMF maintenance therapy on disease remission rate in high-risk type I AIP patients with recurrence within 3 years Secondary research objective: (I) To evaluate the impact on endocrine function; (II) Evaluate the impact on external secretion function; (III) Evaluate the impact on the incidence of malignant tumors; (IV) Adverse reactions; (V) Treatment costs.
Participants will be followed for a total of 36 months. An initial analysis of 12-month follow-up data is planned, with findings intended for dissemination through scientific presentations and/or publication as preliminary results. Follow-up will continue through Month 36, after which the final analysis and dissemination of results are planned.
Peripheral blood samples will be collected during the study for exploratory mechanistic analyses of immune-cell populations and circulating biomarkers. These analyses will characterize biological changes during treatment and explore their associations with disease remission, relapse, and treatment response.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 4
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: XIaonan Shen, Doctor
- Número de teléfono: 18817554263
- Correo electrónico: hgssldsxn@163.com
Ubicaciones de estudio
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Porcelana, 200025
- Reclutamiento
- Ruijin Hospital
-
Contacto:
- Shen, Doctor
- Número de teléfono: 18817554263
- Correo electrónico: hgssldsxn@163.com
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Signed informed consent form with date;
- Promise to comply with research procedures and cooperate with the implementation of the entire process research;
- Age 18 and above, regardless of gender;
- Confirmed as type I AIP and high-risk for recurrence, including the following characteristics: IgG4>4 times the upper limit of normal value before treatment; The serum IgG4 level remained high after GC treatment; Pancreatic diffuse enlargement; IgG4-SC with proximal bile duct involvement; Involvement of extrapancreatic organs;
- Indications for treatment, (1) symptomatic individuals may experience pancreatic involvement (such as obstructive jaundice, abdominal pain, lower back pain, etc.) and extrapancreatic organ involvement (such as jaundice caused by bile duct stenosis, etc.); (2) Asymptomatic individuals, who may develop subclinical AIP (persistent pancreatic mass, liver dysfunction with proximal IgG4 associated sclerosing cholangitis) with severe and irreversible damage to important organs;
- Able to persist and cooperate with research interventions, such as oral medication;
- If it is a woman in the reproductive period, contraception should be used for at least one month before screening, and a commitment should be made to use contraception throughout the entire study period and continue until the specified time after the end of the study
Exclusion Criteria:
- Pregnant/lactating women; Inability or refusal to sign informed consent form;
- History of mental illness;
- Allergy to research interventions;
- With malignant tumors;
- Active hepatitis/tuberculosis and other infectious diseases;
- With underlying diseases that are difficult to control, such as severe heart failure, respiratory failure, etc;
- Within 3 months, use of glucocorticoids or immunosuppressants due to other illnesses
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Comparador activo: Glucocorticoids group
Induction therapy: Prednisone 30mg/d, lasting for 4 weeks, then decreasing by 5mg/d every 2 weeks until maintained at 5mg/d. Peripheral blood samples will also be collected for exploratory mechanistic analyses. |
The study subjects were randomly divided into a GC monotherapy maintenance group and a GC combined with MMF maintenance group in a 1:1 ratio. The randomization sequence was generated online using a computer randomization scheme. Group A was the GC monotherapy maintenance group
Otros nombres:
|
|
Experimental: Glucocorticoids+MMF group
GC: Induction therapy: 30mg/d, lasting for 4 weeks, then decreasing by 5mg/d every 2 weeks until maintained at 5mg/d. At the initial stage of simultaneous treatment, 1.0g-1.5g MMF combined with GC treatment. Peripheral blood samples will also be collected for exploratory mechanistic analyses. |
The study subjects were randomly divided into a GC monotherapy maintenance group and a GC combined with MMF maintenance group in a 1:1 ratio. The randomization sequence was generated online using a computer randomization scheme. Group B was the GC+MMF maintenance group
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Disease remission rate within 3 years in high-risk type I AIP patients receiving glucocorticoid monotherapy versus glucocorticoid combined with MMF maintenance therapy
Periodo de tiempo: 3 years
|
Disease remission is defined as the proportion of patients achieving complete or partial resolution of clinical symptoms, normalization or significant improvement of imaging findings, and reduction of serum IgG4 levels. Remission rate will be compared between the glucocorticoid monotherapy group and the glucocorticoid plus MMF combination therapy group within 3 years of follow-up. |
3 years
|
|
Disease remission rate within 1 years in high-risk type I AIP patients receiving glucocorticoid monotherapy versus glucocorticoid combined with MMF maintenance therapy
Periodo de tiempo: 1 year
|
Disease remission is defined as the proportion of patients achieving complete or partial resolution of clinical symptoms, normalization or significant improvement of imaging findings, and reduction of serum IgG4 levels. Remission rate will be compared between the glucocorticoid monotherapy group and the glucocorticoid plus MMF combination therapy group within 1 years of follow-up. |
1 year
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Changes in endocrine function
Periodo de tiempo: 3 years
|
Endocrine function will be assessed by the following measures: (1) incidence of new-onset diabetes mellitus during the 3-year follow-up period; (2) change from baseline in HbA1c levels; (3) change from baseline in C-peptide levels; (4) change from baseline in insulin secretion capacity. |
3 years
|
|
Changes in external secretion pancreatic function
Periodo de tiempo: 3 years
|
Pancreatic exocrine function will be assessed by the following measures: (1) incidence of pancreatic exocrine insufficiency during the 3-year follow-up period; (2) change from baseline in serum vitamin levels (including vitamin A, D, E); (3) change from baseline in serum 25-OH-D3 levels. |
3 years
|
|
Incidence of malignant tumors
Periodo de tiempo: 3 years
|
Incidence of newly diagnosed malignant tumors, specifically gastrointestinal tumors (including esophageal, gastric, pancreatic, and colorectal tumors), detected by endoscopic examination during the 3-year follow-up period. All tumor diagnoses will be confirmed by histopathological evaluation. |
3 years
|
|
Adverse reactions
Periodo de tiempo: 3 years
|
Adverse reactions including the allergic reactions to drugs |
3 years
|
|
Treatment costs
Periodo de tiempo: 3 years
|
to assess the total treatment costs in 3 years |
3 years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Duowu Zou, Doctor, Ruijin Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Enfermedad crónica
- Atributos de la enfermedad
- Enfermedades autoinmunes
- Enfermedades del sistema inmunológico
- Enfermedades del Sistema Digestivo
- Enfermedades pancreáticas
- Pancreatitis Crónica
- Condiciones Patológicas, Signos y Síntomas
- Pancreatitis
- Pancreatitis autoinmune
- Reaparición
- Efectos fisiológicos de las drogas
- Hormonas
- Hormonas, sustitutos hormonales y antagonistas hormonales
- Acciones farmacológicas
- Acciones y usos químicos
- Compuestos policíclicos
- Espierra
- Embarazos
- Esteroides
- Compuestos de anillo fusionado
- Madreadiediols
- Hormonas de la corteza suprarrenal
- Prednisona
- Glucocorticoides
Otros números de identificación del estudio
Otros números de identificación del estudio
- KY2024-107
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
No plan to share IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .